The Subscribers’ Circle
Join the U.S. Progress Point Subscribers’ Circle
First looks, exclusive content, and more.
-
Americas
-
Asia & Oceania
-
A-I
J-Z
EMEA Thought Leadership
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more -
Middle East & Africa
EMEA Thought Leadership
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more
Regions
-
Americas
-
Asia & Oceania
-
Europe
-
Middle East & Africa
-
Americas
-
Asia & Oceania
-
Europe
Europe
- Adriatic
- Belgium
- Bulgaria
- Czech Republic
- Deutschland
- España
- France
- Greece
- Hungary
- Ireland
- Israel
- Italia
EMEA Thought Leadership
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more -
Middle East & Africa
EMEA Thought Leadership
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more
SOLUTIONS
-
Life Sciences Solutions
-
Healthcare Solutions
-
Medical Device and Diagnostic
-
U.S. Government
Life Sciences Solutions
Bringing together unparalleled healthcare data, advanced analytics, innovative technologies, and healthcare expertise to create intelligent connections that speed the development and commercialization of innovative medicines to improve patient lives.
Learn MoreLife Sciences Solutions
Healthcare Solutions
Helping you create a healthier world for all by harnessing innovation to improve access to and delivery of healthcare with sustainable models.
Learn MoreMedical Device and Diagnostic Solutions
Your world is unique – and quite different from pharma. In the U.S., decision-making has shifted from individual physicians to integrated networks--GPOs, IDNs and payers. These groups have heightened the focus on proving your solution’s value, demanding outcomes analyses and putting pressure on pricing.
Learn MoreMedical Device and Diagnostic Solutions
U.S. Government Solutions
For government agencies and organizations at every level—from federal or national to regional and local—Big Data can have a huge impact on public health.
Learn MoreU.S. Government Solutions
U.S. PROGRESS POINT
A curation of IQVIA's best thinking on topics and trends driving change, disruption, and progress in the United States healthcare market.
LEARN MOREU.S. BLOGS
Get the latest insights on our life sciences, healthcare, and medical technology solutions in the United States. Follow our blog today!
LEARN MOREBlog
A foreword: Accelerating interoperability with USCDI
From the U.S. Progress Point Editorial Board
Aug 03, 2023
Information, and perhaps more specifically data, is the great accelerator of progress and improvement. This is as true in medicine as it is in physics, engineering, education, and just about every other discipline; our ability to understand what is happening enhances and speeds our ability to make it better.
This may seem obvious, but the reality proves otherwise. Consider a typical patient journey; even a standard pathway is likely to be somewhat fragmented, fraught with different doctors, gaps in care due to coverage, a hodgepodge of acute and chronic interactions, and a range of other complexities. The unsurprising result is a system where incomplete health histories are commonplace and timely diagnosis and effective treatment often beyond reach. This is frustrating at best and devastating at worst; consider that the timeline to diagnosis for rare diseases is 3-15 years – an extraordinary and sometimes fatal waiting time for care and relief.
The opportunity to obtain a fuller and easily accessible picture of individual health and needs is at the same time getting closer and more complicated. There is more health data available, through EHRs, personal devices, etc. than ever before, but connecting that data is increasingly hard. Establishing a collaborative environment that satisfies patients’ appetite for a healthcare system that works for them (not in spite of them) and answering the now-federal call for interoperability is an essential step in the right direction.
For patient advocacy groups and medical specialty societies focused on rare diseases in particular, interoperability is paramount. Enhancing data exchange strengthens clinical etiology and quality of life insights allowing for more effective alignment of stakeholders and ultimately better (faster) patient care.
Read more about IQVIA’s perspective on data interoperability, the significance of the United States Core Data for Interoperability (USCDI), and the open (urgent) opportunity for patient advocacy groups and medical specialty societies to be at the leading edge of progress and improvement in healthcare information.
Progress is not an individual activity – it is the fruit of collective thinking and collaborative debate. In that spirit, Progress Point publishes both original work and critical thinking from across the IQVIA organization. The paper referenced in this article was originally published on February 19, 2023 and has been re-published for the benefit of our Progress Point viewers.